Genome-wide allelotypes of familial pancreatic adenocarcinomas and familial and sporadic intraductal papillary mucinous neoplasms

Clinical Cancer Research

Volumn 13, Issue 20, 2007, Pages 6019-6025

  Abe, Tadayoshi ^a   Fukushima, Noriyoshi ^a   Brune, Kieran ^a   Boehm, Corinne ^a   Sato, Norihiro ^a   Matsubayashi, Hiroyuki ^a   Canto, Marcia ^a   Petersen, Gloria M ^b   Hruban, Ralph H ^a   Goggins, Michael ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ADULT; AGED; ALLELOTYPE; ARTICLE; CANCER SUSCEPTIBILITY; CHROMOSOME 19P; CHROMOSOME LOSS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DNA DETERMINATION; FAMILIAL CANCER; FEMALE; GENE; GENE AMPLIFICATION; GENE DELETION; GENE INACTIVATION; GENE LOCATION; GENE LOCUS; GENE LOSS; GENETIC COUNSELING; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRADUCTAL PAPILLARY MUCINOUS CANCER; LASER CAPTURE MICRODISSECTION; MALE; MEN1 GENE; MICROSATELLITE MARKER; MUCINOUS CARCINOMA; PANCREAS ADENOCARCINOMA; PREVALENCE; PRIORITY JOURNAL; SOMATIC CELL; TUMOR SUPPRESSOR GENE; WILD TYPE; XENOGRAFT;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADENOCARCINOMA, PAPILLARY; AGED; AGED, 80 AND OVER; ALLELES; CHROMOSOME MAPPING; FAMILY HEALTH; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME; HETEROZYGOTE; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS;

EID: 35948976564     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0471     Document Type: Article

References (44)

1. Klein AP, Hruban RH, Brune KA, Petersen GM, Goggins M. Familial pancreatic cancer. Cancer J 2001; 7:266-73.
2. Petersen GM, de Andrade M, Goggins M, et al. Pancreatic Cancer Genetic Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev 2006;15:704-10.
3. Klein AP, Brune KA, Petersen GM, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 2004;64:2634-8.
4. Hruban R, Klein A, Eshleman J, Axilbund JE, Goggins M. Familial pancreatic cancer. Expert review in gastroenterology and hepatology. In press 2007.
5. Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996;56:5360-4.
6. Rogers CD, van der Heijden MS, Brune K, et al. The genetics of FANCC and FANCG in familial pancreatic cancer. Cancer Biol Ther 2004;3:167-9. Epub 2004 Feb 1.
7. Rogers CD, Couch FJ, Brune K, et al. Genetics of the FANCA gene in familial pancreatic cancer. J Med Genet 2004;41:e126.
8. Couch FJ, Johnson MR, Rabe K, et al. Germline Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res 2005;65:383-6.
9. van der Heijden MS, Yeo CJ, Hruban RH, Kern SE. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 2003;63:2585-8.
10. Couch FJ, Johnson MR, Rabe KG, et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2007;16: 342-6.
11. Murphy KM, Brune KA, Griffin C, et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in17%. Cancer Res 2002;62:3789-93.
12. Pogue-Geile KL, Chen R, Bronner MP, et al. Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS Med 2006;3:e516.
13. Klein AP, de Andrade M, Hruban RH, et al. Linkage analysis of chromosome 4 in families with familial pancreatic cancer. Cancer Biol Ther 2007;6:320-3. Epub 2007 Mar 15.
14. Earl J, Yan L, Vitone LJ, et al. Evaluation of the 4q32-34 locus in European familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2006;15:1948-55.
15. Salaria SN, Illei P, Sharma R, et al. Palladin is overexpressed in the non-neoplastic stroma of infiltrating ductal adenocarcinomas of the pancreas, but is only rarely overexpressed in neoplastic cells. Cancer Biol Ther 2007;6:324-8. Epub 2007 Mar 24.
16. Klein AP, Beaty TH, Bailey-Wilson JE, Brune KA, Hruban RH, Petersen GM. Evidence for a major gene influencing risk of pancreatic cancer. Genet Epidemiol 2002;23:133-49.
17. Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997;276:404-7.
18. Khalid A, Pal R, Sasatomi E, et al. Use of microsatellite marker loss of heterozygosity in accurate diagnosis of pancreaticobiliary malignancy from brush cytology samples. Gut 2004;53:1860-5.
19. Khalid A, McGrath KM, Zahid M, et al. The role of pancreatic cyst fluid molecular analysis in predicting cyst pathology. Clin Gastroenterol Hepatol 2005;3: 967-73.
20. Khalid A, Nodit L, Zahid M, et al. Endoscopic ultrasound fine needle aspirate DNA analysis to differentiate malignant and benign pancreatic masses. Am J Gastroenterol 2006;101:2493-500.
21. Schoedel KE, Finkelstein SD, Ohori NP. K-Ras and microsatellite marker analysis of fine-needle aspirates from intraductal papillary mucinous neoplasms of the pancreas. Diagn Cytopathol 2006;34:605-8.
22. Iacobuzio-Donahue CA, van der Heijden MS, Baumgartner MR, et al. Large-scale allelotype of pancreaticobiliary carcinoma provides quantitative estimates of genome-wide allelic loss. Cancer Res 2004;64:871-5.
23. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 2006;10:1199-210; discussion 210-1.
24. Canto MI, Goggins M, Hruban RH, et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 2006;4:766-81; quiz 665. Epub 2006 May 6.
25. Canto MI, Goggins M, Yeo CJ, et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2004;2: 606-21.
26. Salaria SN, Illei P, Sharma R, et al. Palladin is overexpressed in the non-neoplastic stroma of infiltrating ductalad enocarcinomas of the pancreas, but is only rarely overexpressed in neoplastic cells. Cancer Biol Ther 2007;6:324-8. epub Mar 24.
27. Rook MS, Delach SM, Deyneko G, Worlock A, Wolfe JL. Whole genome amplification of DNA from laser capture-microdissected tissue for high-throughput single nucleotide polymorphism and short tandem repeat genotyping. Am J Pathol 2004;164:23-33.
28. Dean FB, Hosono S, Fang L, et al. Comprehensive human genome amplification using multiple displacement amplification. Proc Natl Acad Sci U S A 2002; 99:5261-6.
29. Sato N, Maitra A, Fukushima N, et al. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res 2003;63:4158-66.
30. Calhoun ES, Hucl T, Gallmeier E, et al. Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays. Cancer Res 2006;66:7920-8.
31. Calhoun ES, Jones JB, Ashfaq R, et al. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol 2003;163:1255-60.
32. van der Heijden MS, Brody JR, Gallmeier E, et al. Functional defects in the fanconi anemia pathway in pancreatic cancer cells. Am J Pathol 2004;165:651-7.
33. Su GH, Hruban RH, Bansal RK, et al. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol 1999;154:1835-40.
34. Hahn SA, Schutte M, Hoque ATMS, et al. DPC4, a candidate tumor-suppressor gene at 18q21.1. Science 1996;271:350-3.
35. Kinzler KW, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 1997;386: 761-3.
36. Miyaki M, Seki M, Okamoto M, et al. Genetic changes and histopathological types in colorectal tumors from patients with familial adenomatous polyposis. Cancer Res 1990;50:7166-73.
37. Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006;6: 17-32.
38. van Heek NT, Meeker AK, Kern SE, et al. Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol 2002;161:1541-7.
39. Luttges J, Galehdari H, Brocker V, et al. Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis. Am J Pathol 2001;158:1677-83.
40. Sato N, Rosty C, Jansen M, et al. STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol 2001;159:2017-22.
41. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006;7:21-33.
42. Sato N, Matsubayashi H, Abe T, Fukushima N, Goggins M. Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling. Clin Cancer Res 2005;11: 4681-8.
43. Iacobuzio-Donahue CA, Klimstra DS, Adsay NV, et al. Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. Am J Pathol 2000;157:755-61.
44. Axilbund JE, Brune KA, Canto MI, Brehon BC, Wroblewski LD, Griffin CA. Patient perspective on the values of genetic counseling for familial pancreatic cancer. Hereditary Cancer Clin Practice 2005;3: 115-22.